Savara Inc
NASDAQ:SVRA
Savara Inc
Income from Continuing Operations
Savara Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Income from Continuing Operations
-$82.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.3B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$479m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-28%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$4.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
-$535.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.4B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
29%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Income from Continuing Operations?
Income from Continuing Operations
-82.9m
USD
Based on the financial report for Sep 30, 2024, Savara Inc's Income from Continuing Operations amounts to -82.9m USD.
What is Savara Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-12%
Over the last year, the Income from Continuing Operations growth was -70%. The average annual Income from Continuing Operations growth rates for Savara Inc have been -22% over the past three years , -8% over the past five years , and -12% over the past ten years .
You don't have any saved screeners yet